Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H26N6O4S |
Molecular Weight | 506.5788 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COc1cc2c(c(-c3ccccn3)c1OC)c(=N)[nH]c(n2)N4CCc5c(cccc5NS(=O)(=O)C)C4
InChI
InChIKey=OLYXPBZBZBVRGD-UHFFFAOYSA-N
InChI=1S/C25H26N6O4S/c1-34-20-13-19-22(21(23(20)35-2)18-8-4-5-11-27-18)24(26)29-25(28-19)31-12-10-16-15(14-31)7-6-9-17(16)30-36(3,32)33/h4-9,11,13,30H,10,12,14H2,1-3H3,(H2,26,28,29)
Molecular Formula | C25H26N6O4S |
Molecular Weight | 506.5788 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17932223
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17932223
Taprizosin (also known as UK-338,003) is an alpha1A-adrenoceptor antagonist that was developed for the treatment of benign prostatic hyperplasia. However, this compound possesses poor oral absorption.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): the rational use of ex vivo intestine to predict in vivo absorption. | 2008 Jan |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 06:34:40 UTC 2021
by
admin
on
Sat Jun 26 06:34:40 UTC 2021
|
Record UNII |
EQ8YV2D86Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29713
Created by
admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
EQ8YV2D86Y
Created by
admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
|
PRIMARY | |||
|
210538-44-6
Created by
admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
|
PRIMARY | |||
|
210538-44-6
Created by
admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
|
PRIMARY | |||
|
CHEMBL401796
Created by
admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
|
PRIMARY | |||
|
6433102
Created by
admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
|
PRIMARY | |||
|
8286
Created by
admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
|
PRIMARY | |||
|
C66580
Created by
admin on Sat Jun 26 06:34:40 UTC 2021 , Edited by admin on Sat Jun 26 06:34:40 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE |
WEAK
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||